Advertisement
Open Access 07-03-2025 | Kidney Cancer | Invited Review
Image-guided percutaneous ablative treatments for renal cell carcinoma
Published in: European Radiology
Login to get accessPlease log in to get access to this content
Appendix
Available only for authorised users
Literature
1.
go back to reference Bukavina L, Bensalah K, Bray F et al (2022) Epidemiology of renal cell carcinoma: 2022 update. Eur Urol 82:529–542PubMedCrossRef
Bukavina L, Bensalah K, Bray F et al (2022) Epidemiology of renal cell carcinoma: 2022 update. Eur Urol 82:529–542PubMedCrossRef
2.
go back to reference Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30PubMedCrossRef
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30PubMedCrossRef
3.
go back to reference Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG (2021) Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J Urol 206:199–208PubMedCrossRef
Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG (2021) Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J Urol 206:199–208PubMedCrossRef
4.
go back to reference Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386PubMedCrossRef
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386PubMedCrossRef
5.
go back to reference Ljungberg B, Albiges L, Abu-Ghanem Y et al (2022) European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 82:399–410PubMedCrossRef
Ljungberg B, Albiges L, Abu-Ghanem Y et al (2022) European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 82:399–410PubMedCrossRef
6.
go back to reference Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2024) S3-leitlinie diagnostik, therapie und nachsorge des nierenzellkarzinoms, langversion 5.01, 2024, AWMF-Registernummer: 043-017OL
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2024) S3-leitlinie diagnostik, therapie und nachsorge des nierenzellkarzinoms, langversion 5.01, 2024, AWMF-Registernummer: 043-017OL
7.
go back to reference Powles T, Albiges L, Bex A et al (2024) Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 35:692–706PubMedCrossRef
Powles T, Albiges L, Bex A et al (2024) Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 35:692–706PubMedCrossRef
8.
go back to reference Motzer RJ, Jonasch E, Agarwal N et al (2022) Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:71–90PubMedPubMedCentralCrossRef
Motzer RJ, Jonasch E, Agarwal N et al (2022) Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:71–90PubMedPubMedCentralCrossRef
9.
go back to reference Duus LA, Junker T, Rasmussen BS et al (2023) Safety, efficacy, and mid-term oncological outcomes of computed tomography-guided cryoablation of T1 renal cancer. Acta Radiol 64:814–820PubMedCrossRef
Duus LA, Junker T, Rasmussen BS et al (2023) Safety, efficacy, and mid-term oncological outcomes of computed tomography-guided cryoablation of T1 renal cancer. Acta Radiol 64:814–820PubMedCrossRef
10.
go back to reference Sun G, Eisenbrey JR, Smolock AR et al (2024) Percutaneous microwave ablation versus cryoablation for small renal masses (</=4 cm): 12-year experience at a single center. J Vasc Interv Radiol 35:865–873PubMedCrossRef
Sun G, Eisenbrey JR, Smolock AR et al (2024) Percutaneous microwave ablation versus cryoablation for small renal masses (</=4 cm): 12-year experience at a single center. J Vasc Interv Radiol 35:865–873PubMedCrossRef
11.
go back to reference Castellana R, Natrella M, Fanelli G et al (2023) Efficacy and safety of MWA versus RFA and CA for renal tumors: a systematic review and meta-analysis of comparison studies. Eur J Radiol 165:110943PubMedCrossRef
Castellana R, Natrella M, Fanelli G et al (2023) Efficacy and safety of MWA versus RFA and CA for renal tumors: a systematic review and meta-analysis of comparison studies. Eur J Radiol 165:110943PubMedCrossRef
12.
go back to reference Hasegawa T, Yamanaka T, Gobara H et al (2018) Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study. Jpn J Radiol 36:551–558PubMedCrossRef
Hasegawa T, Yamanaka T, Gobara H et al (2018) Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study. Jpn J Radiol 36:551–558PubMedCrossRef
13.
go back to reference Uhlig A, Uhlig J, Trojan L, Kim HS (2020) Stereotactic body radiotherapy for stage I renal cell carcinoma: national treatment trends and outcomes compared to partial nephrectomy and thermal ablation. J Vasc Interv Radiol 31:564–571PubMedCrossRef
Uhlig A, Uhlig J, Trojan L, Kim HS (2020) Stereotactic body radiotherapy for stage I renal cell carcinoma: national treatment trends and outcomes compared to partial nephrectomy and thermal ablation. J Vasc Interv Radiol 31:564–571PubMedCrossRef
14.
go back to reference Hilton A, Kourounis G, Georgiades F (2022) Irreversible electroporation in renal tumours: a systematic review of safety and early oncological outcomes. Urologia 89:329–337PubMedPubMedCentralCrossRef
Hilton A, Kourounis G, Georgiades F (2022) Irreversible electroporation in renal tumours: a systematic review of safety and early oncological outcomes. Urologia 89:329–337PubMedPubMedCentralCrossRef
15.
go back to reference Zlotta AR, Wildschutz T, Raviv G et al (1997) Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol 11:251–258PubMedCrossRef
Zlotta AR, Wildschutz T, Raviv G et al (1997) Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol 11:251–258PubMedCrossRef
16.
go back to reference Chu KF, Dupuy DE (2014) Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14:199–208PubMedCrossRef
Chu KF, Dupuy DE (2014) Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14:199–208PubMedCrossRef
17.
go back to reference Aveta A, Iossa V, Spena G et al (2024) Ablative treatments for small renal masses and management of recurrences: a comprehensive review. Life 14:450
Aveta A, Iossa V, Spena G et al (2024) Ablative treatments for small renal masses and management of recurrences: a comprehensive review. Life 14:450
18.
go back to reference Iannuccilli JD, Dupuy DE, Beland MD, Machan JT, Golijanin DJ, Mayo-Smith WW (2016) Effectiveness and safety of computed tomography-guided radiofrequency ablation of renal cancer: a 14-year single institution experience in 203 patients. Eur Radiol 26:1656–1664PubMedCrossRef
Iannuccilli JD, Dupuy DE, Beland MD, Machan JT, Golijanin DJ, Mayo-Smith WW (2016) Effectiveness and safety of computed tomography-guided radiofrequency ablation of renal cancer: a 14-year single institution experience in 203 patients. Eur Radiol 26:1656–1664PubMedCrossRef
19.
go back to reference Wah TM, Irving HC, Gregory W, Cartledge J, Joyce AD, Selby PJ (2014) Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 113:416–428PubMedCrossRef
Wah TM, Irving HC, Gregory W, Cartledge J, Joyce AD, Selby PJ (2014) Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 113:416–428PubMedCrossRef
20.
go back to reference Mauri G, Mistretta FA, Bonomo G et al (2020) Long-term follow-up outcomes after percutaneous US/CT-guided radiofrequency ablation for cT1a-b renal masses: experience from single high-volume referral center. Cancers (Basel) 12:1183
Mauri G, Mistretta FA, Bonomo G et al (2020) Long-term follow-up outcomes after percutaneous US/CT-guided radiofrequency ablation for cT1a-b renal masses: experience from single high-volume referral center. Cancers (Basel) 12:1183
21.
go back to reference Shakeri S, Raman SS (2019) Trends in percutaneous thermal ablation therapies in the treatment of T1a renal cell carcinomas rather than partial nephrectomy/radical nephrectomy. Semin Intervent Radiol 36:183–193PubMedPubMedCentralCrossRef
Shakeri S, Raman SS (2019) Trends in percutaneous thermal ablation therapies in the treatment of T1a renal cell carcinomas rather than partial nephrectomy/radical nephrectomy. Semin Intervent Radiol 36:183–193PubMedPubMedCentralCrossRef
22.
go back to reference Lubner MG, Brace CL, Hinshaw JL, Lee Jr FT (2010) Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 21:S192–S203PubMedPubMedCentralCrossRef
Lubner MG, Brace CL, Hinshaw JL, Lee Jr FT (2010) Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol 21:S192–S203PubMedPubMedCentralCrossRef
23.
go back to reference Wright AS, Lee Jr FT, Mahvi DM (2003) Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol 10:275–283PubMedCrossRef
Wright AS, Lee Jr FT, Mahvi DM (2003) Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol 10:275–283PubMedCrossRef
24.
go back to reference Sun Y, Wang Y, Ni X et al (2009) Comparison of ablation zone between 915- and 2,450-MHz cooled-shaft microwave antenna: results in in vivo porcine livers. AJR Am J Roentgenol 192:511–514PubMedCrossRef
Sun Y, Wang Y, Ni X et al (2009) Comparison of ablation zone between 915- and 2,450-MHz cooled-shaft microwave antenna: results in in vivo porcine livers. AJR Am J Roentgenol 192:511–514PubMedCrossRef
25.
go back to reference McCloskey C, Jacques A, McCloskey D, Tibballs J (2024) Percutaneous microwave ablation of T1a renal cell carcinomas: a 10-year single-center retrospective review. J Med Imaging Radiat Oncol 68:297–302PubMedCrossRef
McCloskey C, Jacques A, McCloskey D, Tibballs J (2024) Percutaneous microwave ablation of T1a renal cell carcinomas: a 10-year single-center retrospective review. J Med Imaging Radiat Oncol 68:297–302PubMedCrossRef
26.
go back to reference Chlorogiannis DD, Kratiras Z, Efthymiou E et al (2024) Percutaneous microwave ablation versus robot-assisted partial nephrectomy for stage I renal cell carcinoma: a propensity-matched cohort study focusing upon long-term follow-up of oncologic outcomes. Cardiovasc Intervent Radiol 47:573–582PubMedCrossRef
Chlorogiannis DD, Kratiras Z, Efthymiou E et al (2024) Percutaneous microwave ablation versus robot-assisted partial nephrectomy for stage I renal cell carcinoma: a propensity-matched cohort study focusing upon long-term follow-up of oncologic outcomes. Cardiovasc Intervent Radiol 47:573–582PubMedCrossRef
27.
go back to reference Woolley ML, Schulsinger DA, Durand DB, Zeltser IS, Waltzer WC (2002) Effect of freezing parameters (freeze cycle and thaw process) on tissue destruction following renal cryoablation. J Endourol 16:519–522PubMedCrossRef
Woolley ML, Schulsinger DA, Durand DB, Zeltser IS, Waltzer WC (2002) Effect of freezing parameters (freeze cycle and thaw process) on tissue destruction following renal cryoablation. J Endourol 16:519–522PubMedCrossRef
28.
go back to reference Young JL, Khanifar E, Narula N et al (2011) Optimal freeze cycle length for renal cryotherapy. J Urol 186:283–288PubMedPubMedCentralCrossRef
Young JL, Khanifar E, Narula N et al (2011) Optimal freeze cycle length for renal cryotherapy. J Urol 186:283–288PubMedPubMedCentralCrossRef
29.
go back to reference Morkos J, Porosnicu Rodriguez KA, Zhou A et al (2020) Percutaneous cryoablation for stage 1 renal cell carcinoma: outcomes from a 10-year prospective study and comparison with matched cohorts from the National Cancer Database. Radiology 296:452–459PubMedCrossRef
Morkos J, Porosnicu Rodriguez KA, Zhou A et al (2020) Percutaneous cryoablation for stage 1 renal cell carcinoma: outcomes from a 10-year prospective study and comparison with matched cohorts from the National Cancer Database. Radiology 296:452–459PubMedCrossRef
30.
go back to reference Bhagavatula SK, Tuncali K, Shyn PB, Levesque VM, Chang SL, Silverman SG (2020) Percutaneous CT- and MRI-guided cryoablation of cT1 renal cell carcinoma: intermediate- to long-term outcomes in 307 patients. Radiology 296:687–695PubMedCrossRef
Bhagavatula SK, Tuncali K, Shyn PB, Levesque VM, Chang SL, Silverman SG (2020) Percutaneous CT- and MRI-guided cryoablation of cT1 renal cell carcinoma: intermediate- to long-term outcomes in 307 patients. Radiology 296:687–695PubMedCrossRef
31.
go back to reference Auer TA, Müller L, Schulze D et al (2024) CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Radiology 310:e232044PubMedCrossRef
Auer TA, Müller L, Schulze D et al (2024) CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Radiology 310:e232044PubMedCrossRef
32.
go back to reference Siva S, Ali M, Correa RJM et al (2022) 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 23:1508–1516PubMedCrossRef
Siva S, Ali M, Correa RJM et al (2022) 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 23:1508–1516PubMedCrossRef
33.
go back to reference Siva S, Bressel M, Sidhom M et al (2024) Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol 25:308–316PubMedCrossRef
Siva S, Bressel M, Sidhom M et al (2024) Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol 25:308–316PubMedCrossRef
34.
go back to reference Hannan R, McLaughlin MF, Pop LM et al (2023) Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer. Eur Urol 84:275–286PubMedPubMedCentralCrossRef
Hannan R, McLaughlin MF, Pop LM et al (2023) Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer. Eur Urol 84:275–286PubMedPubMedCentralCrossRef
35.
go back to reference Damm R, Streitparth T, Hass P et al (2019) Prospective evaluation of CT-guided HDR brachytherapy as a local ablative treatment for renal masses: a single-arm pilot trial. Strahlenther Onkol 195:982–990PubMedCrossRef
Damm R, Streitparth T, Hass P et al (2019) Prospective evaluation of CT-guided HDR brachytherapy as a local ablative treatment for renal masses: a single-arm pilot trial. Strahlenther Onkol 195:982–990PubMedCrossRef
36.
go back to reference Wagstaff PG, Buijs M, van den Bos W et al (2016) Irreversible electroporation: state of the art. Onco Targets Ther 9:2437–2446PubMedPubMedCentralCrossRef
Wagstaff PG, Buijs M, van den Bos W et al (2016) Irreversible electroporation: state of the art. Onco Targets Ther 9:2437–2446PubMedPubMedCentralCrossRef
37.
go back to reference Srimathveeravalli G, Wimmer T, Monette S et al (2013) Evaluation of an endorectal electrode for performing focused irreversible electroporation ablations in the swine rectum. J Vasc Interv Radiol 24:1249–1256PubMedCrossRef
Srimathveeravalli G, Wimmer T, Monette S et al (2013) Evaluation of an endorectal electrode for performing focused irreversible electroporation ablations in the swine rectum. J Vasc Interv Radiol 24:1249–1256PubMedCrossRef
38.
go back to reference Collettini F, Stephan C, Fischer T, Maxeiner A, Auer TA, Gebauer B (2024) Long-term oncologic outcomes of image-guided irreversible electroporation for localized prostate cancer. Cardiovasc Intervent Radiol. https://doi.org/10.1007/s00270-024-03826-6
Collettini F, Stephan C, Fischer T, Maxeiner A, Auer TA, Gebauer B (2024) Long-term oncologic outcomes of image-guided irreversible electroporation for localized prostate cancer. Cardiovasc Intervent Radiol. https://doi.org/10.1007/s00270-024-03826-6
39.
go back to reference Wah TM, Lenton J, Smith J et al (2021) Irreversible electroporation (IRE) in renal cell carcinoma (RCC): a mid-term clinical experience. Eur Radiol 31:7491–7499PubMedPubMedCentralCrossRef
Wah TM, Lenton J, Smith J et al (2021) Irreversible electroporation (IRE) in renal cell carcinoma (RCC): a mid-term clinical experience. Eur Radiol 31:7491–7499PubMedPubMedCentralCrossRef
40.
go back to reference McClure T, Lansing A, Ferko N et al (2023) A comparison of microwave ablation and cryoablation for the treatment of renal cell carcinoma: a systematic literature review and meta-analysis. Urology 180:1–8PubMedCrossRef
McClure T, Lansing A, Ferko N et al (2023) A comparison of microwave ablation and cryoablation for the treatment of renal cell carcinoma: a systematic literature review and meta-analysis. Urology 180:1–8PubMedCrossRef
41.
go back to reference Atwell TD, Vlaminck JJ, Boorjian SA et al (2015) Percutaneous cryoablation of stage T1b renal cell carcinoma: technique considerations, safety, and local tumor control. J Vasc Interv Radiol 26:792–799PubMedCrossRef
Atwell TD, Vlaminck JJ, Boorjian SA et al (2015) Percutaneous cryoablation of stage T1b renal cell carcinoma: technique considerations, safety, and local tumor control. J Vasc Interv Radiol 26:792–799PubMedCrossRef
42.
go back to reference Gobara H, Matsui Y, Uka M et al (2022) Percutaneous cryoablation combined with prior transcatheter arterial embolization for renal cell carcinomas of 3 cm or larger: a prospective study. Int J Clin Oncol 27:1589–1595PubMedCrossRef
Gobara H, Matsui Y, Uka M et al (2022) Percutaneous cryoablation combined with prior transcatheter arterial embolization for renal cell carcinomas of 3 cm or larger: a prospective study. Int J Clin Oncol 27:1589–1595PubMedCrossRef
43.
go back to reference Salei A, Raymond M, Savage C et al (2023) Transarterial embolization of T1b and T2a renal cell carcinoma prior to percutaneous cryoablation: a retrospective comparative study. Abdom Radiol (NY) 48:773–779PubMedCrossRef
Salei A, Raymond M, Savage C et al (2023) Transarterial embolization of T1b and T2a renal cell carcinoma prior to percutaneous cryoablation: a retrospective comparative study. Abdom Radiol (NY) 48:773–779PubMedCrossRef
44.
go back to reference Chan VW, Osman FH, Cartledge J et al (2022) Long-term outcomes of image-guided ablation and laparoscopic partial nephrectomy for T1 renal cell carcinoma. Eur Radiol 32:5811–5820PubMedPubMedCentralCrossRef
Chan VW, Osman FH, Cartledge J et al (2022) Long-term outcomes of image-guided ablation and laparoscopic partial nephrectomy for T1 renal cell carcinoma. Eur Radiol 32:5811–5820PubMedPubMedCentralCrossRef
45.
go back to reference Neves JB, Warren H, Santiapillai J et al (2024) Nephron sparing treatment (NEST) for small renal masses: a feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot-assisted partial nephrectomy. Eur Urol 85:333–336PubMedCrossRef
Neves JB, Warren H, Santiapillai J et al (2024) Nephron sparing treatment (NEST) for small renal masses: a feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot-assisted partial nephrectomy. Eur Urol 85:333–336PubMedCrossRef
46.
go back to reference Pietersen PI, Stougaard S, Keeley Jr FX et al (2024) Renal function after CT-guided cryoablation of small renal tumours in patients with solitary kidney: an analysis of European Multinational Prospective EuRECA Registry. Cardiovasc Intervent Radiol 47:583–589PubMedPubMedCentralCrossRef
Pietersen PI, Stougaard S, Keeley Jr FX et al (2024) Renal function after CT-guided cryoablation of small renal tumours in patients with solitary kidney: an analysis of European Multinational Prospective EuRECA Registry. Cardiovasc Intervent Radiol 47:583–589PubMedPubMedCentralCrossRef
47.
go back to reference Abu-Ghanem Y, Fernández-Pello S, Bex A et al (2020) Limitations of available studies prevent reliable comparison between tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel. Eur Urol Oncol 3:433–452PubMedCrossRef
Abu-Ghanem Y, Fernández-Pello S, Bex A et al (2020) Limitations of available studies prevent reliable comparison between tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel. Eur Urol Oncol 3:433–452PubMedCrossRef
48.
go back to reference Schullian P, Johnston EW, Putzer D et al (2021) Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection. Eur J Surg Oncol 47:866–873PubMedCrossRef
Schullian P, Johnston EW, Putzer D et al (2021) Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection. Eur J Surg Oncol 47:866–873PubMedCrossRef
49.
go back to reference Junker T, Duus L, Rasmussen BSB et al (2022) Partial nephrectomy versus percutaneous cryoablation of small renal cell carcinomas: a comparison of adverse events in a prospective multicenter cohort study. J Vasc Interv Radiol 33:1375–1383.e1377PubMedCrossRef
Junker T, Duus L, Rasmussen BSB et al (2022) Partial nephrectomy versus percutaneous cryoablation of small renal cell carcinomas: a comparison of adverse events in a prospective multicenter cohort study. J Vasc Interv Radiol 33:1375–1383.e1377PubMedCrossRef
50.
go back to reference Deng W, Chen L, Wang Y et al (2019) Cryoablation versus partial nephrectomy for clinical stage T1 renal masses: a systematic review and meta-analysis. J Cancer 10:1226–1236PubMedPubMedCentralCrossRef
Deng W, Chen L, Wang Y et al (2019) Cryoablation versus partial nephrectomy for clinical stage T1 renal masses: a systematic review and meta-analysis. J Cancer 10:1226–1236PubMedPubMedCentralCrossRef
51.
go back to reference Wu X, Uhlig J, Shuch BM, Uhlig A, Kim HS (2023) Cost-effectiveness of minimally invasive partial nephrectomy and percutaneous cryoablation for cT1a renal cell carcinoma. Eur Radiol 33:1801–1811PubMedCrossRef
Wu X, Uhlig J, Shuch BM, Uhlig A, Kim HS (2023) Cost-effectiveness of minimally invasive partial nephrectomy and percutaneous cryoablation for cT1a renal cell carcinoma. Eur Radiol 33:1801–1811PubMedCrossRef
52.
go back to reference Kim EH, Tanagho YS, Saad NE, Bhayani SB, Figenshau RS (2014) Comparison of laparoscopic and percutaneous cryoablation for treatment of renal masses. Urology 83:1081–1087PubMedCrossRef
Kim EH, Tanagho YS, Saad NE, Bhayani SB, Figenshau RS (2014) Comparison of laparoscopic and percutaneous cryoablation for treatment of renal masses. Urology 83:1081–1087PubMedCrossRef
53.
go back to reference Goyal J, Verma P, Sidana A, Georgiades CS, Rodriguez R (2012) Single-center comparative oncologic outcomes of surgical and percutaneous cryoablation for treatment of renal tumors. J Endourol 26:1413–1419PubMedCrossRef
Goyal J, Verma P, Sidana A, Georgiades CS, Rodriguez R (2012) Single-center comparative oncologic outcomes of surgical and percutaneous cryoablation for treatment of renal tumors. J Endourol 26:1413–1419PubMedCrossRef
54.
go back to reference Jiang K, Tang K, Guo X et al (2017) Laparoscopic cryoablation vs. percutaneous cryoablation for treatment of small renal masses: a systematic review and meta-analysis. Oncotarget 8:27635–27644PubMedPubMedCentralCrossRef
Jiang K, Tang K, Guo X et al (2017) Laparoscopic cryoablation vs. percutaneous cryoablation for treatment of small renal masses: a systematic review and meta-analysis. Oncotarget 8:27635–27644PubMedPubMedCentralCrossRef
55.
go back to reference Pecoraro A, Palumbo C, Knipper S et al (2019) Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pT1b kidney cancer. J Urol 202:1120–1126PubMedCrossRef
Pecoraro A, Palumbo C, Knipper S et al (2019) Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pT1b kidney cancer. J Urol 202:1120–1126PubMedCrossRef
56.
go back to reference Chan VW, Keeley Jr FX, Lagerveld B et al (2022) The changing trends of image-guided biopsy of small renal masses before intervention-an analysis of European multinational prospective EuRECA registry. Eur Radiol 32:4667–4678PubMedPubMedCentralCrossRef
Chan VW, Keeley Jr FX, Lagerveld B et al (2022) The changing trends of image-guided biopsy of small renal masses before intervention-an analysis of European multinational prospective EuRECA registry. Eur Radiol 32:4667–4678PubMedPubMedCentralCrossRef
57.
go back to reference Iezzi R, Contegiacomo A, De Filippis A et al (2024) Proceedings from an international consensus meeting on ablation in urogenital diseases. Insights Imaging 15:267PubMedPubMedCentralCrossRef
Iezzi R, Contegiacomo A, De Filippis A et al (2024) Proceedings from an international consensus meeting on ablation in urogenital diseases. Insights Imaging 15:267PubMedPubMedCentralCrossRef
Metadata
- Title
- Image-guided percutaneous ablative treatments for renal cell carcinoma
- Authors
-
Timo A. Auer
Yasmin Uluk
Rosario Francesco Grasso
Roman Kloeckner
Bernhard Gebauer
Thomas Kroencke
Federico Collettini
- Publication date
- 07-03-2025
- Publisher
- Springer Berlin Heidelberg
- Published in
-
European Radiology
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084 - DOI
- https://doi.org/10.1007/s00330-025-11480-w